Stanford’s Dr. Catherine Blish Joins Deepcell’s Advisory Board

Associate Dean for Basic and Translational Research at Stanford University School of Medicine brings expertise in clinical research to help advance the application of Deepcell technology

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that Dr. Catherine Blish, MD, PhD, of Stanford University has joined Deepcell’s Advisory Board, which is composed of world-renowned experts in biology and life science. Dr. Blish currently serves as Associate Dean for Basic and Translational Research and as Associate Professor of Medicine – Infectious Diseases at the Stanford University School of Medicine.

“The ability to efficiently obtain novel, high resolution insights from cell morphology through artificial intelligence on Deepcell’s platform has the potential to lead to better characterization of cells and a deeper understanding of diseases and, ultimately, to improve patient outcomes,” said Dr. Blish. “Joining Deepcell’s Advisory Board provides an opportunity to help the company’s leadership team and the scientific community explore the broad uses of Deepcell’s technology as a tool for new discoveries, interdisciplinary research, and clinically relevant findings.”

Dr. Blish is a distinguished researcher, having won the NIDA Avant Garde Award for HIV Research and the NIH Director’s New Innovator Award, among other awards and accomplishments. Among other efforts, she is currently leading research into the immune response of COVID-19 patients, and she is a member of Stanford’s Child Health Research Institute and Bio-X, as well as a member of the American Association of Immunologists and a Fellow of the Infectious Diseases Society of America. Dr. Blish is also a Fellow at the Stanford Center for Innovation in Global Health and an Investigator of the Chan Zuckerberg Biohub.

“I am pleased to welcome Dr. Blish to our Advisory Board,” said Maddison Masaeli, co-founder and CEO of Deepcell. “Her expertise in immunology and global health issues, pioneering interdisciplinary studies, and innovative research are highly valuable and complementary to our trusted group of advisors. She has a long and distinguished history of supporting and applying novel technologies to advance life sciences and solve complex biological challenges.”

For more information about Deepcell, go to www.deepcell.com.

About Deepcell

Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Mountain View, CA. For more information, please visit deepcellbio.com.